Why this case matters
Choroideremia is widely recognized as an X-linked inherited retinal disease that predominantly affects males. It progressively damages the retina, retinal pigment epithelium, and choroid—the vascular layer that supplies the outer retina. Female relatives who carry a disease-causing change in the CHM gene have often been described as asymptomatic, or as having relatively mild pigment changes in the retinal periphery.
A 2026 case report in Ophthalmic Genetics challenges the assumption that female carriers will always have mild disease. The report describes a 16-year-old girl with a genetically confirmed CHM mutation who developed severe, permanent central vision loss from scarred choroidal neovascularization (CNV). CNV occurs when abnormal new blood vessels grow beneath or within the retina. These vessels can damage the macula, the small central retinal area needed for reading, recognizing faces, and detailed vision.
For people and families affected by choroideremia, the case underscores an important message: female carriers can sometimes develop clinically significant retinal disease, including complications that threaten central vision during childhood or adolescence.
The reported case: vision loss beginning at age 12
The patient carried a splice-site variant in the CHM gene, reported as c.819 + 1 G > C. Changes in this gene cause choroideremia. Although the report focuses on one individual and cannot establish how often this complication occurs, it provides a striking example of the range of disease severity that can occur in female carriers.
The girl first presented at age 12 after experiencing reduced vision in her right eye. Her visual acuity in that eye was 20/80. Examination of the back of the eye showed widespread pigmentary changes and fibrosis in the central macula. Fibrosis is scar tissue. In this setting, it indicated that a neovascular process had already caused substantial structural injury.
Four years later, at age 16, vision in the affected eye had worsened to 20/250. Retinal imaging showed subretinal hyperreflective material and established subretinal fibrosis, findings consistent with a scarred neovascular membrane. Importantly, the imaging did not show active exudation—fluid or leakage from active abnormal vessels. This distinction matters because the membrane appeared to be in a scarred, inactive stage rather than an actively leaking stage.
Understanding CNV and why scarring is so consequential
Choroidal neovascularization is not unique to choroideremia; it can occur in several retinal conditions. In CNV, fragile new vessels grow from the choroid into spaces where they do not belong. They may leak fluid, blood, and proteins, disrupting the highly organized layers of the macula.
Over time, CNV can lead to fibrosis. Once central scar tissue is established, vision loss can be profound because the scar interferes with the macula’s ability to process sharp, straight-ahead vision. In this case, the patient’s CNV was recognized when fibrosis was already present, and the lesion remained associated with marked visual limitation years later.
CNV has been reported in males with choroideremia across pediatric and adult ages. However, reports in female carriers have previously been limited to adults. The adolescent presentation in this report is therefore especially notable—not only because of the patient’s age, but also because the CNV had already reached a fibrotic, vision-limiting stage.
What the findings mean for families and clinical monitoring
The report supports careful retinal assessment and continued follow-up for female relatives who are known or suspected to carry a CHM mutation. A carrier’s lack of symptoms at one visit does not necessarily predict that central retinal complications will never occur.
Monitoring is particularly important because CNV may be most treatable before it becomes scarred. Retinal imaging can help clinicians look for structural signs of neovascularization, fluid, or other changes in the macula. New distortion, blurring, reduced central vision, or a noticeable difference between the two eyes may warrant prompt evaluation, especially in an at-risk family member.
The case also reinforces the value of genetic testing in families affected by choroideremia. Identifying a familial CHM variant can clarify carrier status and help ensure that female relatives receive ophthalmic surveillance appropriate to their individual risk.
Implications for present and future treatment approaches
This publication does not report treatment of active CNV in this patient. Instead, it illustrates why timing is central to preserving vision. When CNV is identified while active—before extensive fibrosis develops—treatment decisions can focus on controlling vessel activity and leakage. Once a lesion has become an established scar, restoring the central retinal architecture is far more difficult.
More broadly, choroideremia research is increasingly focused on understanding variation in disease expression. Female carriers can have different degrees and patterns of retinal involvement, and this variability may reflect biological processes that influence which X chromosome is active in retinal cells. Cases such as this one emphasize that sex-linked inheritance does not always translate into uniformly mild disease in carriers.
Looking ahead
A single case cannot define the experience of all female CHM carriers, but it expands the clinical picture of choroideremia. It highlights adolescence as a possible period for serious macular complications and argues for surveillance that does not overlook female family members.
As genetic diagnosis, retinal imaging, and choroideremia research continue to advance, documenting uncommon complications will be essential. Earlier recognition of active CNV, before irreversible scarring occurs, may offer the best opportunity to protect central vision in the small number of carriers who develop this serious complication.

